Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Zura Bio announced that it has exceeded enrollment targets in two Phase 2 trials for tibulizumab, TibuSHIELD in hidradenitis suppurativa and TibuSURE in systemic sclerosis, enrolling 247 and over 80 participants respectively. The company plans to initiate a Phase 2 study in a third indication by year-end 2026, with topline data from the current trials expected in Q4 2026 and H1 2027.
Key figures
- Drug Name
- tibulizumab
- Phase Of Trial
- Phase 2
- Cash balance
- $225.6 million
- Tibusure enrollment
- 80
- Tibushield enrollment
- 247
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.